💼 What the Company Does
Merck & Co. (MRK) is a global healthcare company focused on prescription medicines, vaccines, and animal health products. Its business is led by the Pharmaceutical segment, while Animal Health adds a smaller but still meaningful second revenue stream.
The company’s biggest growth engine is Keytruda, its leading cancer drug. Merck also sells important vaccines such as Gardasil and runs a broad animal health business serving livestock and companion animals. In simple terms, Merck makes money by developing high-value drugs, winning regulatory approval, and selling them globally while patent protection lasts.
📊 Financial Highlights
Merck reported $65.0 billion in sales in FY2025, up from $64.2 billion in FY2024 and $60.1 billion in FY2023. The company’s results improved sharply after a weak FY2023, when earnings were heavily affected by unusually large research and development charges.
- FY2025 revenue: $65.0 billion
- FY2025 net income: $18.3 billion
- FY2025 diluted EPS: $7.3
- Main financial pattern: stronger earnings recovery in FY2024 and FY2025 after a distorted FY2023
Merck also remained a strong cash generator, while continuing to spend on acquisitions, research, capital projects, dividends, and share repurchases.
⚠️ Key Risks
The biggest company-specific risk is dependence on Keytruda. When one product contributes a very large share of revenue, any slowdown, pricing pressure, or competition can matter a lot.
- Patent risk: once patents expire, lower-cost generic or biosimilar competition can reduce sales quickly
- Pipeline risk: drug development is expensive, slow, and uncertain
- Pricing risk: government programs and reimbursement pressure can limit pricing power
- Manufacturing and regulatory risk: delays, quality issues, or approval setbacks can hurt results
- China risk: Merck disclosed significantly lower Gardasil/Gardasil 9 sales in China in 2025
For beginners, the simple idea is that Merck needs both current blockbuster drugs and future drug approvals to keep growth going.
📝 MD&A: What Management Emphasized
Management said FY2025 growth was supported mainly by strong performance in oncology (cancer drugs), especially Keytruda, along with contributions from other products and Animal Health. Management also highlighted that profitability improved as prior-year expense distortions became less severe.
- Sales growth came from key pharmaceutical products
- Profitability improved as large prior R&D charges normalized
- Cash flow remained strong enough to support both investment and shareholder returns
- Balance sheet growth reflected acquisitions, higher debt, and rising intangible assets
In plain English, management’s message was that Merck is still growing, still investing heavily, and still using strong cash flow to support both expansion and capital returns.
✅ Takeaway: Merck 10-K Analysis Summary
Merck’s FY2025 10-K shows a large, profitable pharmaceutical company with strong cash flow, a powerful oncology franchise, and an active investment strategy. The business recovered well from an unusually weak FY2023 and ended FY2025 with stronger earnings, more assets, and continued capital returns. At the same time, the company still relies heavily on a few key products, especially Keytruda, which makes patent life, pipeline success, and regulatory execution especially important for long-term investors.
💵 Income Statement Summary
Unit: $m, except EPS in $. Percentages and ratios are rounded to one decimal place. EPS is rounded to one decimal place. Negative values are shown in parentheses.
| Income Statement Summary | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | 60,115 | 64,168 | 65,011 |
| Cost of Goods Sold | 16,126 | 15,193 | 16,382 |
| Gross Profit | 43,989 | 48,975 | 48,629 |
| SG&A | 10,504 | 10,816 | 10,733 |
| Operating Income | 2,355 | 19,912 | 21,218 |
| Non-Operating Income/Expense | (680) | (1,295) | (1,206) |
| Interest Income/Expense | 1,146 | 1,271 | 1,357 |
| Income Before Tax | 1,889 | 19,936 | 21,067 |
| Income Tax | 1,512 | 2,803 | 2,804 |
| Net Income | 365 | 17,117 | 18,254 |
| EPS | 0.1 | 6.7 | 7.3 |
Plain English: Merck’s income statement shows a very unusual 2023, followed by a sharp earnings recovery in 2024 and another step up in 2025. Revenue grew steadily from $60.1bn to $65.0bn over the three-year period, but 2023 profit was crushed by a huge R&D bill. That tells beginners an important lesson: a drug company can still grow sales while reported profit looks temporarily weak if it books large development or deal-related costs. In 2024 and 2025, operating income rebounded strongly as R&D expense normalized, which pushed pretax income, net income, and EPS much higher. Gross profit stayed very strong, showing that Merck still sells high-margin products, while SG&A remained controlled. Structurally, this looks like a business with durable pricing power and strong product economics, but one that can have volatile reported earnings when acquisition-related research spending spikes.
📐 Key Financial Ratios
| Ratio | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| ROE (%) | 0.9 | 40.8 | 36.9 |
| ROA (%) | 0.3 | 15.3 | 14.4 |
| ROTC (%) | 3.2 | 23.9 | 20.8 |
| ROIC (%) | 0.7 | 24.4 | 21.1 |
| Gross Margin (%) | 73.2 | 76.3 | 74.8 |
| Operating Margin (%) | 3.9 | 31.0 | 32.6 |
| Pretax Margin (%) | 3.1 | 31.1 | 32.4 |
| Net Margin (%) | 0.6 | 26.7 | 28.1 |
| Debt-to-Equity Ratio (D/E) (%) | 93.3 | 80.1 | 93.8 |
| Net Debt / EBITDA (x) | 4.5 | 1.0 | 1.3 |
| Interest Coverage Ratio (x) | 2.1 | 15.7 | 15.6 |
| Current Ratio (%) | 125.2 | 136.5 | 153.6 |
| Quick Ratio (%) | 67.9 | 84.3 | 93.0 |
| Fixed Asset to Long-term Capital Ratio (%) | 32.3 | 29.4 | 25.5 |
Plain English: The ratio table shows just how distorted 2023 was. Profitability ratios such as ROE, ROA, ROTC, and ROIC were extremely weak in 2023, then snapped back in 2024 and stayed strong in 2025. That means the weak 2023 result was not the normal earnings power of the business. Margins also tell a clear story: gross margin remained excellent throughout, while operating and net margins jumped once R&D distortion eased. Liquidity improved every year, with both the current ratio and quick ratio moving higher, which suggests Merck had more near-term balance sheet flexibility. Leverage did rise again in 2025, largely because the company added debt while doing acquisitions and returning capital to shareholders, but Net Debt / EBITDA stayed manageable. Interest coverage remained strong in 2024 and 2025, which means operating profit still covered borrowing costs comfortably.
📝 Disclaimer
This article is intended for educational purposes only. It does not constitute financial, investment, or legal advice. All investment decisions involve risks, and readers should conduct their own research or consult with a licensed financial advisor.
👉 Merck & Co. (MRK) FY 2025 10-K Analysis (Filed 2026) | Explained for Beginners